Connect with us

Coronavirus Outbreak

COVID-19 Bigger Blood Clot Threat Than Vaccines, UK Study Finds

The findings showed although there was an increased risk of having a blood clot after having the first doses of either vaccine, it was much greater in someone who had tested positive for COVID-19 caused by the SARS-CoV-2 virus

COVID-19 Bigger Blood Clot Threat Than Vaccines, UK Study Finds
Highlights
  • Vaccines currently in use have been tested in randomised clinical trials
  • The study uses data on over 29 million vaccinated people
  • The study underscores the importance of getting vaccinated

London: A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday (August 27). The research used findings from more than 29 million people who were vaccinated with the first doses of either vaccine between December 2020 and April 2021.

Also Read: Half Of Hospitalised Covid Patients Have Persisting Symptoms After A Year: Lancet Study

The findings showed although there was an increased risk of having a blood clot after having the first doses of either vaccine, it was much greater in someone who had tested positive for COVID-19 caused by the SARS-CoV-2 virus.

People should be aware of these increased risks after COVID-19 vaccination and seek medical attention promptly if they develop symptoms, but also be aware that the risks are considerably higher and over longer periods of time if they become infected with SARS-CoV-2, said Julia Hippisley-Cox, Professor of Clinical Epidemiology and General Practice at the University of Oxford and lead author of the paper.

The study covered thrombocytopenia – a condition with low platelet counts – and thromboembolic events (blood clots) following vaccination for COVID-19, some of the same events which had led to restricted use in a number of countries of the Oxford/AstraZeneca vaccine – being produced and administered in India as Covishield. Writing in the ‘British Medical Journal’ (BMJ), the researchers detail the findings from over 29 million people vaccinated with first doses of either the ChAdOx1 nCov-19 or Oxford/AstraZeneca vaccine or the BNT162b2 mRNA or Pfizer/BioNTech vaccine.

They conclude that with both of these vaccines, for short time intervals following the first dose, there are increased risks of some haematological and vascular adverse events leading to hospitalisation or death. The authors further note that the risk of these adverse events is substantially higher and for a longer period of time, following infection from the SARS-CoV-2 coronavirus than after either vaccine.

Also Read: What Are COVID-19 Breakthrough Infections? How Long Does Immunity Last After COVID-19 Vaccination? An Expert Explains

This research is important as many other studies, while useful, have been limited by small numbers and potential biases. Electronic healthcare records, which contain the detailed recording of vaccinations, infections, outcomes and confounders, have provided us with a rich source of data with which to perform a robust evaluation of these vaccines, and compare to risks associated with COVID-19 infection, explains Prof Hippisley-Cox.

All of the coronavirus vaccines currently in use have been tested in randomised clinical trials, which are unlikely to be large enough to detect very rare adverse events. When rare events are uncovered, then regulators perform a risk-benefit analysis of the medicine; to compare the risks of the adverse events if vaccinated versus the benefits of avoidance of the disease – in this case, COVID-19. Aziz Sheikh, Professor of Primary Care Research & Development and Director of the Usher Institute at the University of Edinburgh and a co-author of the paper, said,

This enormous study, using data on over 29 million vaccinated people, has shown that there is a very small risk of clotting and other blood disorders following the first dose COVID-19 vaccination. Though serious, the risk of these same outcomes is much higher following SARS-CoV-2 infection. On balance, this analysis therefore clearly underscores the importance of getting vaccinated to reduce the risk of these clotting and bleeding outcomes in individuals, and because of the substantial public health benefit that COVID-19 vaccinations offer.

In the paper, the team of authors from the University of Oxford, University of Leicester, Guys and St Thomas’ NHS Foundation Trust, the Intensive Care National Audit & Research Centre, the London School of Hygiene and Tropical Medicine, the University of Cambridge, the University of Edinburgh and the University of Nottingham, compared rates of adverse events after vaccination with Pfizer/BioNTech and Oxford/AstraZeneca vaccines with rates of the same events after a positive SARS-CoV-2 test result.

For this, they used routinely collected electronic health records to evaluate the short-term risks (within 28 days) of hospital admission with thrombocytopenia, venous thromboembolism (VTE) and arterial thromboembolism (ATE), using data collected from across England between December 1, 2020 and April 24, 2021. Other outcomes studied were cerebral venous sinus thrombosis (CVST), ischemic stroke, myocardial infarction and other rare arterial thrombotic events.

Also Read: Experts On WHO Team Say Search For COVID Origins Has Stalled

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

World

24,24,98,327Cases
20,40,54,102Active
3,35,14,449Recovered
49,29,776Deaths
Coronavirus has spread to 195 countries. The total confirmed cases worldwide are 24,24,98,327 and 49,29,776 have died; 20,40,54,102 are active cases and 3,35,14,449 have recovered as on October 22, 2021 at 5:24 am.

India

3,41,43,236 15,786Cases
1,75,7453,086Active
3,35,14,449 18,641Recovered
4,53,042 231Deaths
In India, there are 3,41,43,236 confirmed cases including 4,53,042 deaths. The number of active cases is 1,75,745 and 3,35,14,449 have recovered as on October 22, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

65,98,218 1,573

27,899 1,434

64,30,394 2,968

1,39,925 39

Kerala

48,88,523 8,733

82,093 1,240

47,79,228 9,855

27,202 118

Karnataka

29,84,849 365

9,017 86

29,37,848 443

37,984 8

Tamil Nadu

26,91,797 1,164

13,790 268

26,42,039 1,412

35,968 20

Andhra Pradesh

20,62,303 493

5,500 66

20,42,476 552

14,327 7

Uttar Pradesh

17,10,068 10

107 5

16,87,062 14

22,899 1

West Bengal

15,83,646 833

7,535 44

15,57,090 775

19,021 14

Delhi

14,39,488 22

311 1

14,14,087 21

25,090

Odisha

10,37,056 524

4,336 51

10,24,422 573

8,298 2

Chhattisgarh

10,05,773 38

206 21

9,91,995 16

13,572 1

Rajasthan

9,54,395 2

36 2

9,45,405 4

8,954

Gujarat

8,26,353 13

156 20

8,16,110 33

10,087

Madhya Pradesh

7,92,721 12

88 6

7,82,110 6

10,523

Haryana

7,71,125 9

131 2

7,60,945 11

10,049

Bihar

7,26,042 6

30 0

7,16,351 6

9,661

Telangana

6,69,739 183

3,967 1

6,61,829 183

3,943 1

Assam

6,07,811 384

3,762 152

5,98,087 228

5,962 4

Punjab

6,02,135 22

226 6

5,85,358 27

16,551 1

Jharkhand

3,48,526 40

166 24

3,43,225 16

5,135

Uttarakhand

3,43,787 14

176 0

3,36,213 14

7,398

Jammu And Kashmir

3,31,386 87

814 14

3,26,143 73

4,429

Himachal Pradesh

2,22,138 202

1,452 58

2,16,955 140

3,731 4

Goa

1,77,765 59

618 21

1,73,790 35

3,357 3

Puducherry

1,27,564 43

454 7

1,25,258 50

1,852

Manipur

1,23,051 81

1,346 14

1,19,800 94

1,905 1

Mizoram

1,15,944 737

10,034 229

1,05,510 962

400 4

Tripura

84,369 18

105 10

83,448 8

816

Meghalaya

83,210 52

735 26

81,034 76

1,441 2

Chandigarh

65,315 3

26 2

64,469 1

820

Arunachal Pradesh

55,065 22

140 2

54,645 20

280

Sikkim

31,819 19

185 10

31,241 9

393

Nagaland

31,670 11

250 5

30,743 15

677 1

Ladakh

20,896 10

43 9

20,645 1

208

Dadra And Nagar Haveli

10,678 2

4 2

10,670

4

Lakshadweep

10,365

0 0

10,314

51

Andaman And Nicobar Islands

7,646

7 0

7,510

129

Coronavirus Outbreak: Full CoverageTesting CentresFAQs

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Highlights From The 12-Hour Telethon

Leaving No One Behind

Mental Health

Environment

Join Us